Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03262935 · ClinicalTrials.gov registry record · Phase 3
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
A Phase 3 study, sponsored by Byondis B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 437
- Enrollment target
NCT03262935 is a Phase 3 study that has completed, run by Byondis B.V.. The registered enrollment target is 437 participants.
The verdict
NCT03262935, a Phase 3 study, has completed, sponsored by Byondis B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 437 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that SYD985 \[(vic-)trastuzumab duocarmazine\] is superior to physician's choice in prolonging progression free survival.
Interventions
- DRUG (vic-)trastuzumab duocarmazine
- DRUG Physician's choice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 437 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03262935
The ClinicalTrials.gov registry entry for NCT03262935 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 437 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Byondis B.V., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which (vic-)trastuzumab duocarmazine is the first listed.
NCT03262935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03262935 about?
NCT03262935 is a clinical study titled "SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer". The purpose of this study is to demonstrate that SYD985 \[(vic-)trastuzumab duocarmazine\] is superior to physician's choice in prolonging progression free survival.
What is the current status of trial NCT03262935?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 437 participants. The study started on 2017-12-15. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03262935?
The interventions under investigation include: (vic-)trastuzumab duocarmazine (DRUG), Physician's choice (DRUG).
Who is sponsoring clinical trial NCT03262935?
This trial is sponsored by Byondis B.V., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.